Avelox Settlements

Hundreds of Avelox lawsuits have been filed on behalf of individuals who were diagnosed with peripheral neuropathy and other complications allegedly related to their use of the fluoroquinolone antibiotic. While it is too early to predict if any of these cases will result in Avelox settlements, any such agreements could provide patients with compensation to cover medical bills and other damages related to their alleged injuries.

Contact an Avelox Attorney Today

The nationwide law firm of Bernstein Liebhard LLP represents individuals who were allegedly harmed by Avelox and other fluoroquinolone antibiotics. Avelox cases currently under investigation include peripheral neuropathy claims, as well as those involving aortic aneurysm and aortic dissection. To discuss a case with our legal team today, please call (888) 994-5118.

Avelox and Peripheral Neuropathy

The majority of pending Avelox lawsuits involve a serious and potentially permanent form of nerve damage called peripheral neuropathy. As of December 2016, more than 700 peripheral neuropathy lawsuits had been filed against the manufacturers of Avelox, Cipro and Levaquin in a federal multidistrict litigation currently underway in the U.S. District Court, District of Minnesota. Hundreds of additional cases are pending in state courts around the country.

Peripheral neuropathy affects the nerves that transmit information between the central nervous system (the brain and spinal cord) and every other part of the body. You may be able to file a peripheral neuropathy lawsuit – and participate in any subsequent Avelox settlements – if you were diagnosed with this condition after using the medication. Symptoms commonly associated with peripheral neuropathy include:

  • Numbness or tingling in the extremities
  • Pricking sensations (paresthesia)
  • Muscle weakness
  • Intense or distorted experience of touch (allodynia)
  • Burning pain (especially at night)
  • Muscle wasting
  • Paralysis
  • Organ or gland dysfunction

Mention of peripheral neuropathy was first added to the labels of all fluoroquinolone antibiotics in 2004. However, it wasn’t until August 2013 that the labels were updated to note that nerve damage cause by the antibiotics could be permanent, or that language characterizing  peripheral neuropathy as a rare side effect was removed from their prescribing information.

Avelox and Aortic Injuries

Several studies have suggested that fluoroquinolone antibiotics might increase the risk of aortic dissection and aortic aneurysm. These life-threatening complications could be related to collagen degradation, which is thought to play a role in other fluoroquinolone side effects, such as tendon ruptures. While the litigation involving fluoroquinolones and aortic injuries is in its earliest stages, it is important to seek legal advice if you or a loved one were diagnosed with either of these conditions while using Avelox, especially if you wish to participate in any future settlements.

How Can an Avelox Settlement Help?

Compensation from Avelox settlements could include payment for medical bills, lost wages, disability and other injury-related damages. Bernstein Liebhard LLP currently represents a number of fluoroquinolone plaintiffs, and our Firm continues to provide free, no-obligation case reviews to those interested in pursuing Avelox lawsuits. To learn more, please call our office today at (888) 994-5118.

  1. gov (2014) “Peripheral Neuropathy Fact Sheet” https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Peripheral-Neuropathy-Fact-Sheet
  2. FDA (2013) “FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection.” http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm
  3. JAMA Internal Medicine (2015) “Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone”  http://archinte.jamanetwork.com/article.aspx?articleid=2451282
  4. BMJ (2015) “Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study” http://bmjopen.bmj.com/content/5/11/e010077.full
Last Modified: January 10, 2017

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest

Skip to content